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Context: Observational studies relating circulating 25-hydroxyvitamin D (25OHD) and dietary vi-
tamin D intake to cardiovascular disease (CVD) have reported conflicting results.
Objective:Our objective was to investigate the association of 25OHD, dietary vitamin D, PTH, and
adjusted calcium with CVD and mortality in a Scottish cohort.
DesignandSetting:TheMIDSPANFamily Study is aprospective studyof1040menand1298women
from the West of Scotland recruited in 1996 and followed up for a median 14.4 yr.
Participants: Locally resident adult offspring of a general population cohort were recruited from
1972–1976.
Main OutcomeMeasures: CVD events (n 416) and all-cause mortality (n 100) were evaluated.
Results: 25OHD was measured using liquid chromatography-tandem mass spectrometry in avail-
able plasma (n 2081). Median plasma 25OHDwas 18.6 ng/ml, and median vitamin D intake was
3.2 g/d (128 IU/d). Vitamin D deficiency (25OHD 15 ng/ml) was present in 689 participants
(33.1%). There was no evidence that dietary vitamin D intake, PTH, or adjusted calcium were
associated with CVD events or with mortality. Vitamin D deficiency was not associated with CVD
(fully adjustedhazard ratio1.00; 95%confidence interval0.77–1.31). Resultswere similar after
excluding patients who reported an activity-limiting longstanding illness at baseline (18.8%) and
those taking any vitamin supplements (21.7%). However, there was some evidence vitamin D
deficiency was associated with all-cause mortality (fully adjusted hazard ratio  2.02; 95% confi-
dence interval  1.17–3.51).
Conclusion: Vitamin D deficiency was not associated with risk of CVD in this cohort with very low
25OHD. Future trials of vitamin D supplementation in middle-aged cohorts should be powered to
detectdifferences inmortalityoutcomesaswell asCVD. (JClinEndocrinolMetab97: 0000–0000, 2012)
Many observational studies suggest that low circulat-ing levels of 25-hydroxyvitamin D (25OHD), the
circulating storage form of vitamin D, are associated with
increased incidence of cardiovascular disease (CVD) (1–
6), death (5–8), and noncardiovascular chronic diseases
(9), although a recent Institute of Medicine (IOM) report
highlights inconsistencies in the literature regarding the
definition of vitamin D deficiency and insufficiency (10).
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An apparently high prevalence of vitamin D-deficient in-
dividuals in many populations (11, 12) has led to calls for
widespread supplementation programs to correct vitamin
D deficiency, although the IOM report also highlights a
lack of data from randomized controlled trials (RCTs) to
support these calls (10).
Although several studies have reported no association
between 25OHD and CVD (13–15), studies reporting an
association have generally been better cited thus far (16).
These inconsistencies require more data to clarify associ-
ations and reconcile these with findings from RCTs (10).
There is also a need to determine the association of
25OHDwithCVDandmortality independentofPTHand
calcium (17). Although observational data cannot prove
causality, estimates of associations with a range of end-
points may guide priority endpoints for future purpose-
designed RCTs.
If vitamin D deficiency is an important determinant of
CVDordeath, onemay expect that these associationsmay
be more pronounced in populations with generally low
UVB sunlight exposure. With a Northerly latitude, fre-
quent substantial cloud cover, and low levels of processed
food fortification with vitamin D, cohorts from Scotland
have low levels of 25OHD (12) and are attractive for in-
vestigating the association of 25OHDwith a range of dis-
eases. The MIDSPAN Family Study is a cohort of 30- to
59-yr-olds living near Paisley in the West of Scotland in
1996. The cohort was recruited from a defined geograph-
ical area, mitigating against confounding of vitamin D
status by latitude.
Our hypothesis was that, given existing RCT data sug-
gesting that vitamin D deficiency may not be causal in
CVD (10), after more complete adjustment for a large
range of potential confounders and exclusion of those
with chronic baseline disease in the MIDSPAN Family
Study, 25OHD would not be associated with CVD or
mortality.
Materials and Methods
Recruitment
TheMIDSPAN Family Study took place betweenMarch and
December 1996. The study recruited adult sons and daughters of
coupleswhohad participated in theRenfrew/Paisley prospective
cohort study between 1972 and 1976, which consisted of 7049
men and 8353women aged between 45 and 64 yr andwho lived
in the towns of Renfrew and Paisley (18). Renfrew and Paisley
are two similar towns situated on the southwest perimeter of the
City of Glasgow within a large postindustrial area. The latitude
of Paisley is 55° 84 min N. The aim was to establish a study
investigating transgenerational causes of chronic disease as well
as to establish a contemporary cohort study. The recruitment
process of the MIDSPAN Family Study has been described in
detail elsewhere (18, 19). In brief, offspring of the married cou-
ples identifiedwithin the Renfrew/Paisley cohort, aged 30–59 yr
and living locally, formed the eligible population (3202offspring
from1767 families). In all, 1040male and 1298 female offspring
from 1477 families took part, and all participants were Cauca-
sian, with 99.7% living locally (exclusion of those who did not
live locally did not alter reported results). Ineligible offspring
(n 1813) included those too old or too young, those not living
locally, those with problematic addresses, or those who died
before the study commenced. The original MIDSPAN cohort
was representative of the catchment area in being characterized
by high levels of socioeconomic deprivation, which was (and is)
more severe than Scotland as a whole but less severe than the
most deprived areas of Glasgow.
The offspring were invited, in random order, to complete a
detailed questionnaire and attend a screening examination, sim-
ilar to their parents 20 yr previously. All information on physical
activity, smoking, occupation, diet, socioeconomic status, and
alcohol consumption were based on self-reported answers from
standard questionnaires (20, 21). Socioeconomic factors were
occupational social class coded according to the Registrar Gen-
eral’s classification, highest level of education, and the Carstairs
deprivation index (an index of deprivation in a specific postcode
based on census data) (22). Measurements of height, weight,
waist, hip, forced expiratory volume in 1 sec (FEV1), and blood
pressures were obtained by a qualified research nurse who also
collected nonfasting venous blood samples. A semiquantitative
food frequency questionnaire [modified from that of Yarnell et
al. (23)] and specifically validated for the antioxidant vitamins
against plasma levels was used (24). The frequency of consump-
tion of 60 foods and food groups was reported as one to seven
times per week, fortnightly, or rarely/never. Nutrient (including
fat, fiber, and vitamin D) intakes were calculated by a computer
program, which multiplied the food frequency by standard por-
tion size and by nutrient values fromUnitedKingdom food com-
position tables, usingMcCance andWiddowson version 6 (Food
Standards Agency), which includes a potency factor for vitamin
Dmetabolites inmeat (25). Participantswere askedwhether they
routinely took vitamin supplements; there were seven different
possible category codings indicating type of supplement inges-
tion. All seven categories contained preparations that may have
contained vitamin D, and thus in sensitivity analysis, all people
who reported taking supplements were excluded from analyses.
Participants were asked (yes or no) in the baseline questionnaire
whether they had any longstanding illness disability or infirmity
andwhether this illness or disability limited their activities in any
way. If the answer to both questions was affirmative, we defined
the individual as having an activity-limiting longstanding illness.
Blood samples obtained were spun down, plasma separated, ali-
quoted, and stored at 80 C for subsequent analysis.
Ethical approval for the study was obtained from the Argyll
and Clyde Health Board Local Research Ethics Committee and
from Greater Glasgow Health Board Local Research Ethics
Committee. Informed written consent was obtained for veni-
puncture, sample storage, and record linkage.
Events definition
Participants were followed up for a median 14.4 yr. Scotland
has a National Health Service (NHS) offering universal health-
care to all citizens, which is free at point of care. Virtually all
healthcare (especially emergency care and that relating to
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chronic illness) is delivered in NHS institutions. Endpoints were
identified byperiodic reviewof the cohort (last reviewcompleted
up to December 31, 2010) using a national database: the Infor-
mation Services Division NHS record linkage for Scotland. The
Information Services Division-linked database contains infor-
mation on Scotland’s morbidity records (SMRs) for acute spe-
cialty day case and inpatient discharges from hospital (SMR01)
since January1981 with InternationalClassificationofDiseases
(ICD)-9 codings 390–459 and ICD-10 codings I00–I99 for in-
cident CVD events, i.e. any disease of the circulatory system.
Death certificates were obtained from the NHS Central Register
where the participants were flagged. For the present paper, the
primary CVD endpoint was any CVD event (ICD-10 I00–I99)
coded on discharge or on the death certificate. A sensitivity anal-
ysis of the CVD endpoint included only events where CVD was
the principal reason for hospitalization or death. For coronary
heart disease events, an audit of SMR01 shows codings were
recorded with 94.2% accuracy [95% confidence interval (CI)
3.0%], 93.4% sensitivity, and 99.2% completeness, with cor-
responding figures for cerebrovascular disease of 94.8% (95%
CI4.4%), 91.1%, and 96.0% (26). The secondary endpoint
was all-causemortality,with a sensitivity analysis for deaths that
were principally causedbyCVD,or principally causedbydisease
that was not cardiovascular in origin (according to the under-
lying cause of death on the death certificate).
Circulating biomarker measurement
Measurement of 25OHDwas performed on EDTA-anticoagu-
latedplasmavia ahigh-throughputmethod for themeasurementof
25OHD3 and -D2 using a gold-standard automated solid-phase
extraction procedure with liquid chromatography-tandem mass
spectrometry (27). Our method is currently in routine clinical use
and is calibratedandcontrolledusing reagents fromChromsystems
GmbH (Manchester, UK). Results are reported as total 25OHD
(25OHD2  25OHD3); more than 99% of participants had an
undetectable 25OHD2, which is commensurate with results ob-
served in routine NHS use. The lower limit of sensitivity was re-
ported as 4 ng/ml for both 25OHD3 and total 25OHD. Plasma
PTH was measured by electrochemiluminescence on an Elecsys
2010 (RocheDiagnostics, BurgessHill, UK) using themanufactur-
er’s calibrators andcontrols.Coefficients of variationwere5.6%at
57 pg/ml and 3.8% at 189 pg/ml. Albumin-corrected calcium was
calculated as measured total calcium (millimoles per liter)  0.02
[40  serum albumin (grams per liter)]. Serum calcium was
measured on fresh samples by automated clinical biochemis-
try platforms.
Statistical methods
All subjects with available data were used inmodels fitted for
25OHD, vitamin D intake, PTH, and corrected calcium mea-
sures, respectively.Medians and interquartile ranges (IQR)were
used to summarize nonnormally distributed data, means and SD
for normally distributed data, and frequencies and percentages
for summary of categorical data. Demographic measurements
were compared between subjects who went on to become CVD
cases and noncases using the two-sample t test for continuous
variables and Fisher’s test for categorical variables. Normal dis-
tributions were achieved by taking logarithms of positively
skewed variables, including 25OHD. Relationships between log
25OHD and baseline continuous characteristics were assessed
by age- and sex-adjusted Pearson correlation coefficients. Pre-
dictions for 25OHD, vitamin D intake, PTH, and adjusted cal-
cium from a linear regression model adjusted for month were
plotted to detect seasonality. Associations of 25OHD, vitaminD
intake, PTH, and adjusted calcium with the risk of CVD and
mortalitywere investigated, both by linear andnonlinearmodels
in the form of quadratic curves and penalized regression splines.
The associations of these markers with CVD risk and mortality
were summarized using hazard ratios (HRs) derived from Cox
proportional hazards models (proportional hazard assumptions
were met in all cases), using continuous models (HR per 1-SD
increase) for circulating 25OHD, vitamin D intake, PTH, and
adjusted calcium and using a categorical model for 25OHD de-
ficiency. There is no universally accepted current definition of
vitamin D deficiency, so we used a cutoff previously reported to
be strongly associated with CVD risk [15 ng/ml (37.5 mmol/
liter)] (2, 4). Cox models were adjusted for classical and non-
classical risk factors in four models as defined in the relevant
tables.All available datawere used, resulting in smaller complete
data sets for models with more complex adjustment due tomiss-
ing covariate measurements. When analyses were restricted to
complete data sets for allmodels, the estimatedassociationswere
unchanged in all models (data not shown).
P values 0.05 were taken to be indicative of a true associ-
ation. Cox model effect estimates are reported as the HR asso-
ciated with a 1-SD increase for continuous predictors (on a log
scale), or for being vitamin D deficient, with a 95% CI. No
adjustmentsweremade formultiple comparisons.Analyseswere
carried out using R for Windows version 2.12.1.
Results
Baseline characteristics and associations
Two participants were excluded from the analyses be-
cause no consent for record linkage was obtained. Due to
sample attrition, and the high volume of samples required
for 25OHDmeasurement, total 25OHDwasmeasured in
2081 samples (89%of the total).Datameasurementswere
completed for 2335, 2194, and 2188 individuals for
dietary vitamin D intake, PTH, and adjusted calcium,
respectively.
Cohort median 25OHD and mean vitamin D dietary
intake were generally low, with medians of 18.6 ng/ml
and 3.2 g/d (128 IU/d), respectively, and 689 partic-
ipants (33.1%) were vitamin D deficient (15 ng/ml).
Estimates of dietary sources of vitaminD intake showed
that the primary determinant of dietary vitamin D was
fish consumption (Supplemental Fig. 1, published on
The Endocrine Society’s Journals Online web site at
http://jcem.endojournals.org).
Those who smoked, were deprived, had prevalent cor-
onary heart disease or longstanding illness at baseline, did
not meet fiber intake guidelines (18 g/d), consumed more
fat, or were sedentary were more likely to be deficient in
vitamin D (Table 1). Participants with vitamin D defi-
ciency also had lower creatinine levels and lower FEV1
output. Plasma samples taken during the winter or spring
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TABLE 1. Baseline characteristics by vitamin D deficiency
Characteristic Not deficient (>15 ng/ml) Deficient (15 ng/ml) P value
Age
n 1392 689 0.163
yr 45.2 (6.2) 44.9 (6.1)
Gender
n 1392 689 0.073
Male 635 (46%) 285 (42%)
Female 757 (54%) 404 (58%)
Smoking
n 1392 689 0.001
Never 698 (50%) 277 (40%)
Former 417 (30%) 171 (25%)
Current 277 (20%) 241 (35%)
Systolic BP
n 1387 688 0.705
mm Hg 125.5 (116.0–136.0) 125.0 (115.5–137.0)
Total cholesterol
n 1391 688 0.533
mmol/liter 5.2 (4.6–5.8) 5.2 (4.7–5.8)
HDL-cholesterol
n 1203 606 0.651
mmol/liter 1.4 (1.2–1.6) 1.4 (1.1–1.6)
Triglycerides
n 1387 687 0.799
mmol/liter 1.2 (0.9–1.9) 1.2 (0.9–1.9)
Diabetes
n 1392 689 0.856
Yes 18 (1%) 9 (1%)
No 1374 (99%) 680 (99%)
Glucose
n 1392 687 0.393
mmol/liter 5.1 (4.8–5.5) 5.1 (4.7–5.5)
BMI
n 1391 689 0.768
kg/m2 25.5 (23.2–28.2) 25.6 (22.6–29.2)
Waist circumference
n 1392 688 0.456
cm 85.2 (75.7–94.5) 85.3 (74.7–96.2)
Education
n 1389 687 0.193
School 662 (48%) 349 (51%)
Tertiary 727 (52%) 338 (49%)
Social class
n 1392 689 0.102
Nonmanual 970 (70%) 455 (66%)
Manual 422 (30%) 234 (34%)
Deprivation
n 1387 689 0.001
1–2 336 (24%) 128 (19%)
3–5 797 (57%) 394 (57%)
6–7 254 (18%) 167 (24%)
CRP
n 1311 633 0.019
mg/liter 0.8 (0.4–2.0) 0.9 (0.4–2.5)
Baseline CHD
n 1390 687 0.001
No 1239 (89%) 577 (84%)
Yes 151 (11%) 110 (16%)
Activity-limiting longstanding illness
n 1392 689 0.004
No 1156 (83%) 535 (78%)
Yes 236 (17%) 154 (22%)
(Continued)
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were more likely to be below the threshold for deficiency.
As expected, circulating 25OHD was considerably lower
among those who were deficient, whereas vitamin D con-
sumption was also slightly lower and circulating PTH
slightly higher. At baseline, circulating 25OHDwasmod-
erately positively correlated with vitamin D intake and
inversely correlated with PTH after adjustment for age
and sex but was not associated with adjusted calcium
(Supplemental Table 1).
Seasonal variation in circulating 25OHD, vitamin D
intake, PTH, and adjusted calcium was assessed based
on month of blood sample collection (Fig. 1). Month
was a significant term in linear models fitted for 25OHD,
PTH, and adjusted calcium, indicating evidence of sea-
sonal variation (P  0.001 for all), although there was
no evidence dietary vitamin D was associated with
month. These trends were unaltered by exclusion of
those taking supplements (data not shown). Due to re-
cruitment not taking place in January or February, the
median 25OHD of 18.6 ng/ml is likely to be an over-
estimate of the year-round median within the popula-
tion this cohort represents.
TABLE 1. Continued
Characteristic Not deficient (>15 ng/ml) Deficient (15 ng/ml) P value
Season
n 1392 689 0.001
Winter 104 (7%) 95 (14%)
Spring 191 (14%) 259 (38%)
Summer 554 (40%) 219 (32%)
Autumn 543 (39%) 116 (17%)
Creatinine
n 1370 669 0.001
mol/liter 98.9 (13.2) 95.4 (12.4)
Predicted FEV1
n 1372 662 0.001
% of predicted 97.8 (13.2) 94.1 (14.3)
Fiber
n 1391 688 0.002
18 g/d 1058 (76%) 479 (70%)
18 g/d 333 (24%) 209 (30%)
% fat from diet
n 1311 638 0.001
% 34.1 (5.8) 35.2 (5.7)
Alcohol intake
n 1392 689 0.016
UK U/wk 8.0 (3.0–18.0) 7.0 (1.5–16.0)
Current medication
n 1392 689 0.846
No 1376 (99%) 681 (99%)
Yes 16 (1%) 8 (1%)
Insulin medication
n 1392 689 0.512
No 1384 (99%) 687 (100%)
Yes 8 (1%) 2 (0%)
Physical activity
n 1392 689 0.001
Active 1084 (78%) 470 (68%)
Sedentary 308 (22%) 219 (32%)
25OHD
n 1392 689 0.001
ng/ml 22.9 (18.6–28.5) 11.0 (8.7–13.0)
Vitamin D intake
n 1392 689 0.001
g/d 3.3 (2.4–4.7) 3.0 (2.1–4.1)
PTH
n 1364 674 0.001
pg/ml 28.6 (22.4–35.5) 30.9 (24.8–39.2)
Adjusted calcium
n 1354 668 0.687
mmol/liter 2.3 (0.1) 2.3 (0.1)
Values are mean (SD), number (percent), or median (IQR). BP, Blood pressure; BMI, body mass index; CHD, coronary heart disease; CRP, C-reactive
protein; HDL, high-density lipoprotein.
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Association with CVD
Classical CVD risk factors generally differed between
CVD cases and noncases in the expected directions (Supple-
mental Table 2).On simple univariable comparison, theme-
dian 25OHD concentration was 18.4 ng/ml (IQR  12.3–
25.1 ng/ml) among cases and 18.7 ng/ml (IQR 13.3–25.5
ng/ml) among noncases (P  0.32). Estimated vitamin D
intake, corrected calcium, andPTHwere
also no different inCVDcases compared
with noncases (Supplemental Table 2).
Both linearandnonlinearassociations
of 25OHD, vitamin D intake, PTH, and
adjusted calcium with CVD were inves-
tigated. None of these factors showed
strong evidence of a relationship with
CVDevents in linearmodels adjusted for
age, sex, season, and otherCVD risk fac-
tors (Table 2) or by nonlinearmodels us-
ing splineorquadratic curves (data not
shown). Restriction of the definition of
CVD events to those thatwere the prin-
cipal reason for hospitalization or
death (n  309 events) did not materi-
ally alter results (no association in any
model; data not shown).
In analysis adjusted for age, sex, and
season only, therewas some evidence for
an association of vitamin D deficiency
(15 ng/ml) with CVD events (HR 
1.31; 95% CI 1.07–1.62) (Table 3). However, this associ-
ation was attenuated to null after adjustment for classical and
nonclassical CVD risk factors (HR 1.00; 95% CI 0.77–
1.31). Restriction of the definition of CVD events to primary
cause for hospitalization or death did notmaterially alter asso-
ciations (adjusted HR 0.91; 95%CI 0.66–1.24).
FIG. 1. Mean predicted values (and 95% CI) for circulating 25OHD, vitamin D intake, PTH, and
adjusted calcium, from March to December (no baseline samples taken in January or February).
TABLE 2. Cox proportional hazards models for risk of CVD, with relative associations of 1-SD increases in circulating
25OHD (log scale), dietary vitamin D intake (log scale), PTH (log scale), and adjusted calcium, using various
adjustment models
Model A Model B Model C Model D
25OHDa
HR (95% CI) 0.89 (0.81–0.99) 0.96 (0.85–1.08) 1.06 (0.93–1.21) 1.07 (0.94–1.23)
N 2081 1801 1522 1492
n 416 341 297 293
Vitamin D intakea
HR (95% CI) 0.97 (0.88–1.06) 0.95 (0.86–1.06) 0.95 (0.83–1.07) 0.94 (0.83–1.08)
N 2333 1954 1641 1492
n 462 366 318 293
PTHa
HR (95% CI) 1.06 (0.97–1.17) 1.07 (0.96–1.19) 1.03 (0.92–1.16) 1.05 (0.92–1.18)
N 2194 1903 1609 1492
n 434 358 315 293
Adjusted calcium
HR (95% CI) 1.02 (0.92–1.12) 0.99 (0.89–1.11) 1.00 (0.89–1.12) 1.01 (0.89–1.13)
N 2188 1904 1635 1492
n 440 362 317 293
Model A was adjusted for age, sex, and season. Model B was additionally adjusted for diabetes, glucose, smoking, systolic blood pressure, total
cholesterol, high-density cholesterol, and BMI. Model C was additionally adjusted for triglycerides, waist circumference, creatinine, C-reactive
protein, insulin, highest educational level (tertiary level or other), social class, deprivation category, percent fat from diet, alcohol intake, high and
low fiber in diet, current medication (ACE inhibitors, antihypertensives, aspirin, insulin, oral hypoglycemics, sartans, and statins), baseline coronary
heart disease, low baseline physical activity, and percent predicted FEV1. Model D was additionally adjusted for 25OHD, vitamin D intake, PTH, and
adjusted calcium where appropriate. N  number at risk; n  number of events.
a Modeled on log scale.
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Association with all-cause mortality
Dietary vitamin D intake, PTH, and adjusted calcium
showed no strong evidence of associations with all-cause
mortality in linear models (Table 4) or by spline or qua-
dratic curves (figures not shown).
Circulating 25OHD was inversely associated with all-
cause mortality, such that higher levels had a borderline as-
sociationwith lowermortality; in fully adjusted linearmod-
els of log 25OHD, the HR per 1-SD increase was 0.74 (95%
CI  0.56–0.99). No nonlinear associations were demon-
strated by quadratic or spline curves (data not shown).
Plasma25OHDdeficiency (15ng/ml)was associatedwith
all-cause mortality in both age-, sex-, and season-adjusted
(HR  3.03; 95% CI  2.01–4.57) and in fully adjusted
analyses (HR  2.02; 95% CI  1.17–3.51) (Table 5). To
reduce the possibility of reverse causality, we excluded those
with self-reported activity-limiting longstanding illness at
baseline, although thisdidnotalter associations. Inaddition,
exclusionof those takingvitaminsupplementsatbaselinedid
not materially alter associations.
To elucidate the association of vitamin D deficiency
with cause-specific mortality, we investigated the associ-
ation with principal CVD mortality (CVD the principal
cause of death), and mortality where CVD was not the
principal cause.Among thosewhowere deficient, the fully
adjusted HR for principal CVDmortality (n 12 events)
was 8.13 (95%CI 1.26–52.7)whereas the risk for prin-
cipal non-CVD mortality (n 58 events) was 1.82 (95%
CI  0.99–3.35) (Supplemental Table 3).
Discussion
In the MIDSPAN Family Study, median 25OHD was in-
sufficient at 18.6 ng/ml, perhaps compounded by low di-
etary vitamin D intake. We observed no association of
TABLE 3. Cox proportional hazards models for vitamin D deficiency associations with the risk of any CVD event, for
all patients with available measures on circulating 25OHD (n  2074) and for a subgroups of patients
Model A Model B Model C Model D
Full cohort
25OHD deficiency (15 ng/ml), n  689
HR (95% CI) 1.31 (1.07–1.62) 1.24 (0.98–1.57) 1.01 (0.78–1.32) 1.00 (0.77–1.31)
N 2081 1801 1522 1492
n 416 341 297 293
Subgroup cohort (no activity-limiting
longstanding illness at baseline)
25OHD deficiency (15 ng/ml), n  535
HR (95% CI) 1.24 (0.96–1.59) 1.16 (0.87–1.54) 0.98 (0.71–1.35) 0.94 (0.68–1.31)
N 1691 1466 1239 1216
n 298 241 206 204
Adjustment models A–D are described in Table 2. N  number at risk; n  number of events.
TABLE 4. Cox proportional hazards models for risk of all-cause mortality, with relative associations of 1-SD increases
in circulating 25OHD (log scale), dietary vitamin D intake (log scale), PTH (log scale), and adjusted calcium, using
various adjustment models
Model A Model B Model C Model D
25OHDa
HR (95% CI) 0.57 (0.46–0.70) 0.68 (0.54–0.86) 0.77 (0.59–1.01) 0.74 (0.56–0.99)
N 2081 1801 1522 1492
n 100 79 71 70
Vitamin D intakea
HR (95% CI) 1.01 (0.84–1.22) 1.01 (0.81–1.26) 1.04 (0.80–1.36) 1.05 (0.79–1.41)
N 2333 1954 1641 1492
n 120 90 79 70
PTHa
HR (95% CI) 0.90 (0.74–1.10) 1.05 (0.83–1.31) 0.95 (0.74–1.21) 0.86 (0.66–1.13)
N 2194 1903 1609 1492
n 106 86 78 70
Adjusted calcium
HR (95% CI) 1.04 (0.86–1.26) 0.98 (0.79–1.22) 0.97 (0.76–1.23) 0.87 (0.67–1.14)
N 2188 1904 1635 1492
n 109 88 79 70
Adjustment models A–D are described in Table 2. N  number at risk; n  number of events.
a Modeled on log scale.
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vitaminD deficiency (15 ng/ml) with CVD events in any
model. However, death rates were twice as high in those
who were deficient, even after exclusion of those with
activity-limiting longstanding illness at baseline and those
taking supplements, although power to investigate these
associations with cause-specific mortality was limited.
It couldbeargued that the lackof associationwithCVD
we observe may be because so few of our population had
optimal 25OHD levels of more than 30 ng/ml, and so we
may lack a full range of concentrations with which to
compare deficient with sufficient and optimal. However,
the association observed between vitamin D deficiency
and mortality is in line with other general population co-
horts (4–6) and a previous cohort that has reported an
association between 25OHD and mortality in Scotland
(28). It is also of note that there is evidence both for (29)
and against (30–32) an association of 25OHD with ca-
rotid artery intima-media thickness (a putative surrogate
of CVD risk status). Formal meta-analysis after publica-
tion of more observational data will allow assessment of
the likelihood of publication bias within the literature as
well as to assess the association of vitamin D deficiency
with CVD death and nonfatal CVD.
Despite some studies reporting associations of vitamin
D deficiency with increased CVD risk (1–6), other (gen-
erally smaller) studies have reported no association of cir-
culating 25OHDwith CVD (13–15). We note that in our
study, vitamin D deficiency was associated with increased
all-cause mortality and perhaps with CVD mortality. We
have previously shown that other CVD risk markers such
as inflammatory markers and obesity are more strongly
associated with CVD death than with nonfatal CVD
events (33, 34). It is therefore of real interest that several
of the best cited studies linking 25OHD to CVD used a
fatal CVD endpoint (1–3, 5, 6). Whether vitamin D defi-
ciency renders a CVD event more likely to be fatal (i.e. is
causal) or whether poor health (and consequently low vi-
tamin D) leads to a reduction in the likelihood of survival
of acute CVD requires additional study.
The issue of causality cannot be inferred from an ob-
servational study alone. The associations we have ob-
served suggest a strong effect (if the association is causal).
However, this finding is in direct contrast to existing data
frommeta-analysis of randomized trials of vitaminD sup-
plementation, which suggest (primarily in the elderly,
where the greatest effect size is likely to be observed due to
reduced risk of hospitalization for fractures) a very small
effect of supplements on mortality (35). We attempted to
reduce the likelihoodof confounding and reverse causality
by exclusion of those with activity-limiting longstanding
illness and adjusting for a wide range of potential con-
founders. Ultimately, evidence of benefit of higher circu-
lating 25OHDwill come fromMendelian randomization
studies and supplementation data from trials designed to
investigate mortality. Whether or not trials of additional
supplementation in countries where vitamin D fortifica-
tion of foodstuffs is routine (such as VITamin D and
OmegA-3 TriaL, VITAL, in the United States) (http://
www.vitalstudy.org) will confer benefit is unclear. In this
context, more vitamin D supplementation trials in coun-
trieswhere vitaminD fortification in foodstuff is generally
low may be additionally informative.
Of interest, dietary vitamin D intake in our study was
also not associated with CVD events or with CVD mor-
TABLE 5. Cox proportional hazards models for vitamin D deficiency associations and the risk of all-cause mortality,
in all patients with available measures on circulating 25OHD (n  2074) and for a subgroup of patients with no
activity-limiting longstanding illness reported at baseline (n  1684)
Model A Model B Model C Model D
Full cohort
25OHD deficiency (15 ng/ml), n  689
HR (95% CI) 3.03 (2.01–4.57) 2.42 (1.50–3.90) 2.01 (1.18–3.43) 2.02 (1.17–3.51)
N 2081 1801 1522 1492
n 100 79 71 70
Sensitivity analysis: no activity-limiting
longstanding illness at baseline
25OHD deficiency (15 ng/ml), n  535
HR (95% CI) 3.23 (1.97–5.31) 2.75 (1.55–4.86) 2.49 (1.33–4.65) 2.33 (1.23–4.44)
N 1691 1466 1239 1216
n 69 56 51 50
Sensitivity analysis: patients not taking
vitamin supplements at baseline
25OHD deficiency (15 ng/ml), n  579
HR (95% CI) 3.38 (2.16–5.29) 2.73 (1.63–4.58) 2.05 (1.13–3.73) 2.04 (1.10–3.79)
N 1630 1401 1199 1179
n 86 68 61 60
Adjustment models A–D are described in Table 2. N  number at risk; n  number of events.
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tality. This is an important observation in a population
where comparatively little food is supplemented with vi-
tamin D; average MIDSPAN intake is less than 130 IU/d,
whereas the IOMrecommends an intakeof 600 IU/d in the
United States (10). Guidelines in the United Kingdom ap-
pear to generally assume vitamin D consumption in the
United Kingdom is inadequate (36, 37), which will gen-
erally appear to be true compared with the United States
where fortification is far more widespread. It is possible
that our data extracted from food frequency question-
naires underestimate vitamin D consumption specifically.
However, recent data among Scottish mothers (38) and
postmenopausal women (39) suggest that, based on food
questionnaire data extraction, dietary vitamin D intake in
Scotland is typically in the range of 100–150 IU/d.
Strengths of the present study include the use of a well-
phenotyped cohort study from a single geographic loca-
tion to minimize confounding by latitude, in a country
where food is not routinely supplementedwith vitaminD.
Circulating 25OHD was measured using gold-standard
liquid chromatography-tandemmass spectrometry meth-
ods currently used in an externally quality controlled rou-
tine NHS laboratory. Endpoints were identified on fol-
low-up using national record linkage databases, and all
routine risk factors showed strongassociationswithCVD,
thereby lending external validity to our findings. Potential
weaknesses include the small number of individuals in the
study with conventionally optimal circulating 25OHD.
Blood samples taken were nonfasting, and diabetes was
self-reported, meaning there may have been some undi-
agnosed baseline diabeteswe did not detect and adjust for.
Dietary vitamin D intake was estimated from food fre-
quency questionnaires that measured intake of only 60
foods or food groups, although this method has been val-
idated for use for antioxidant vitamins (against circulating
plasma levels) (24).
In conclusion, in a cohort of middle-aged Scottish peo-
ple with low dietary vitamin D intake and low circulating
25OHD, we report no association with CVD events, al-
though there was some evidence that 25OHD deficiency
was associated with mortality. These data should help
guide the design of trials that, based on our findings,
should be sufficiently powered to assess the impact of vi-
tamin D supplementation on all-cause mortality in mid-
dle-aged populations.
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